China's Sinovac Set To Stage World's First Clinical Trials For Vaccine Defense To Enterovirus 71, Which Threatens Children Across Asia
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Leading Chinese vaccine developer Sinovac Biotech has filed an application with national drug regulators in Beijing to conduct clinical trials on the world's first defense to human enterovirus 71
You may also be interested in...
Chinese Tank Commanders, Megacity Teens First In Line For A/H1N1 Vaccine
BEIJING - As the Beijing-based Sinovac Biotech ramps up production of the world's first publicly available A/H1N1 vaccine, China's Minister of Health has identified special sectors of the country's 1.3-billion-strong populace that will receive inoculations first, within the next several days
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).